DECIBEL THERAPEUTICS INC's ticker is DBTX and the CUSIP is 24343R106. A total of 1 filers reported holding DECIBEL THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $226,380 | +378.6% | 58,800 | +275.5% | 0.00% | – |
| Q1 2023 | $47,296 | +41.9% | 15,661 | -3.7% | 0.00% | – |
| Q4 2022 | $33,335 | -85.9% | 16,261 | -76.3% | 0.00% | – |
| Q3 2022 | $237,000 | -18.3% | 68,600 | -0.6% | 0.00% | – |
| Q2 2022 | $290,000 | +51.8% | 69,000 | +9.8% | 0.00% | – |
| Q1 2022 | $191,000 | -31.0% | 62,825 | +5.5% | 0.00% | – |
| Q4 2021 | $277,000 | -17.6% | 59,570 | +36.8% | 0.00% | – |
| Q3 2021 | $336,000 | -9.9% | 43,535 | +0.4% | 0.00% | – |
| Q2 2021 | $373,000 | +17.3% | 43,350 | +54.8% | 0.00% | – |
| Q1 2021 | $318,000 | – | 28,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP III, LLC | 3,139,685 | $14,600,000 | 3.65% |
| Samsara BioCapital, LLC | 826,422 | $3,843,000 | 0.75% |
| Orbimed Advisors | 4,945,192 | $22,995,000 | 0.30% |
| Alphabet Inc. | 1,636,258 | $7,609,000 | 0.18% |
| Casdin Capital, LLC | 1,170,048 | $5,441,000 | 0.15% |
| HARVARD MANAGEMENT CO INC | 328,798 | $1,529,000 | 0.14% |
| Bronte Capital Management Pty Ltd. | 157,216 | $731,000 | 0.05% |
| ATLAS CAPITAL ADVISORS LLC | 41,025 | $190,766,000 | 0.03% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 263,600 | $1,226,000 | 0.02% |
| Woodline Partners LP | 275,001 | $1,279,000 | 0.02% |